Interferon-Induced Protein With Multiple Tetratricopeptide Repeats 3 Is Associated With Response to Chemotherapy and Recurrence but Not With Survival.
Interferon-Induced Protein With Multiple Tetratricopeptide Repeats 3 Is Associated With Response to Chemotherapy and Recurrence but Not With Survival.
复制标题
具有多个四三肽重复序列 3 的干扰素诱导蛋白与化疗反应和复发相关，但与生存无关
DOI：
10.1097/mpa.0000000000001691
复制
发表时间：
2020
期刊：
影响因子：
2.9
通讯作者：
Popp FC
中科院分区：
文献类型：
--
作者：
Popp MC;Klippstein M;Lohneis P;Kalinski T;Quaas A;Bludau M;Wang Z;Waldschmidt D;Kunzmann V;Damanakis A;Gebauer F;Zhao Y;Bruns CJ;Popp FC
目的 干扰素诱导的具有多个四三肽重复序列 3 的蛋白 (IFIT3) 似乎与胰腺癌的预后相关。在这里，我们阐明 IFIT3 表达的异质性是否影响之前的 IFIT3 分析。方法这项回顾性研究分析了通过手术从 2 个独立患者队列中获取的胰腺癌组织样本。患者接受初次手术（n = 72）或接受新辅助化疗（n = 12）。免疫组织化学评估了 IFIT3 表达及其异质性。作为补充，我们分析了公开的转录组数据 (n= 903)。结果在初次切除的肿瘤中，16.4% 是异质的。与 IFIT3 阳性肿瘤患者相比，IFIT3 阴性肿瘤患者的生存期并不长。对公开数据的分析证实了这一结果。发生肺转移的患者预后最好（4.8年），与肝转移相比，IFIT3表达显着降低（P=0.0117）。接受新辅助治疗的 IFIT3 阴性患者的无病生存期较长（1.2 年 vs 0.3 年，P = 0.0081）。结论 低 IFIT3 表达与较长生存期无关。组织微阵列分析的不同结果可以用肿瘤异质性来解释。作为单一生物标志物，IFIT3不适合预测疾病预后。肺转移的复发和对新辅助化疗的反应与 IFIT3 低表达相关。
ObjectivesThe interferon-induced protein with multiple tetratricopeptide repeats 3 (IFIT3) seems to be associated with the prognosis in pancreatic cancer. Here we clarify whether the heterogeneity of IFIT3 expression affects previous IFIT3 analysis.MethodsThis retrospective study analyzes pancreatic cancer tissue samples retrieved by surgery from 2 independent patient cohorts. Patients underwent either primary surgery (n= 72) or received neoadjuvant chemotherapy (n= 12). Immunohistochemistry assessed IFIT3 expression and its heterogeneity. Complementarily, we analyzed publicly available transcriptomic data (n= 903).ResultsOf the primarily resected tumors, 16.4% were heterogeneous. Patients with IFIT3-negative tumors did not survive longer compared with patients with IFIT3-positive tumors. An analysis of publicly available data confirmed this result. Patients developing lung metastases had the best prognosis (4.8 years) with significantly lower IFIT3 expression compared with liver metastasis (P= 0.0117). Patients receiving neoadjuvant therapy who are IFIT3 negative had a longer disease-free survival (1.2 vs 0.3 years, P= 0.0081).ConclusionsLow IFIT3 expression is not associated with longer survival. Divergent results from tissue microarray analyses could be explained with tumor heterogeneity. As a single biomarker, IFIT3 is not suitable for predicting disease prognosis. Recurrence of lung metastases and response to neoadjuvant chemotherapy are associated with low IFIT3 expression.
影响因子：
3.8
作者：
Popp FC;Popp MC;Zhao Y;Betzler C;Kropf S;Garlipp B;Benckert C;Kalinski T;Lippert H;Bruns CJ
通讯作者：
Bruns CJ
影响因子：
2.6
作者：
Zheng, Biao;Ohuchida, Kenoki;Nakamura, Masafumi
通讯作者：
Nakamura, Masafumi
干扰素诱导蛋白四三肽重复序列 3 (IFIT3) 升高是胰腺导管腺癌的不良预后标志物
影响因子：
3.6
作者：
Yue Zhao;Annelore Altendorf-Hofmann;Ioannis Pozios;Peter Camaj;Therese Däberitz;Xiaoyan Wang;Hanno Niess;Hendrik Seeliger;Felix Popp;Christopher Betzler;Utz Settmacher;Karl-Walter Jauch;Christiane Bruns;Thomas Knösel
通讯作者：
Thomas Knösel